source
- Oberland pours up to $400M into MeiraGTx eye gene therapiesThe funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.BioPharma Dive · 21d ago↗ source
- Kailera says obesity pill succeeds in late-stage trial in ChinaThe drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.BioPharma Dive · 21d ago↗ source
- STAT+: The crumbling employer-based health insurance systemToday's D.C. Diagnosis newsletter covers maintaining diversity in drug trials and troubling trends in employer-based health insurance.STAT · 21d ago↗ source